Georgia's Online Cancer Information Center

Find A Clinical Trial

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Cancer Type
Hematopoietic Malignancies
Non-Hodgkin Lymphoma
Solid Tumor
Unknown Primary
Trial Phase
Phase I
Phase II
18 Years and older, Male and Female
Study Type
Protocol IDs
RNK05047-01 (primary)
Study Sponsor
Ranok Therapeutics (Hangzhou) Co., Ltd.


This is a first in human, Phase 1/2 open-label multi-center, dose escalation and
expansion study to evaluate the safety, tolerability, PK, PD and efficacy of RNK05047
when administered an intravenous (IV) infusion to subjects with advanced solid tumors,
including diffuse large B-cell lymphoma (DLBCL).

This is a 2-part study (dose escalation, cohort expansion) with sequential enrollment.


In Part 1, enrolled subjects will receive IV RNK05047 once weekly for 3 consecutive weeks
in a 4-week cycle (no treatment in the fourth week). The dose-escalation phase will
follow a standard 3+3 design, with 3 subjects enrolled into the first dosing cohort to
receive RNK05047 at the starting dose of 0.75 mg/kg.

In Part 2, once RP2D has been established, additional subjects (3 to 5 cohorts of
approximately 15 subjects per cohort) will be enrolled in the cohort-expansion phase of
the study. Tumor types for these cohorts will be determined based on data from the
dose-escalation phase of the study and emerging results from preclinical studies or other
scientific data. These dose expansion cohorts in all groups may be done concurrently.


  1. Pathologically documented locally advanced or metastatic solid tumor
  2. Refractory or intolerant to all available standard-of-care therapies for advanced disease
  3. Measurable disease
  4. Adequate tumor sample
  5. ECOG Performance Status of 0 or 1
  6. BMI = 18 kg/m2
  7. Adequate liver, renal, hematologic, and coagulation parameters
  8. Negative serum pregnancy test (for women of childbearing potential) at Screening and a negative urine or serum pregnancy test on Day 1 prior to the first infusion
  9. Males and females of childbearing potential must agree to use a highly effective method of contraception during treatment and for at least 4 months after the last dose of study treatment.
  10. Must be able to understand and comply with the conditions of the protocol and must have read and understood the consent form and provided written informed consent.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University

1365 Clifton Road NE
Building C
Atlanta, GA 30322

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.